May 11, 2020
Amneal Reports First Quarter 2020 Financial Results
‒ Q1 2020 Net Revenue of $ 499 million; GAAP Net Income of $115 million; Diluted Earnings per Share of…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 11, 2020
Magellan Health Reports First Quarter 2020 Financial Results
PHOENIX–(BUSINESS WIRE)–Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the first quarter ended March 31, 2020, as summarized…
May 11, 2020
Enhertu designated breakthrough therapy in the U.S. for HER2 gastric cancer
Daiichi Sankyo and AstraZeneca’s Enhertu trastuzumab has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.
May 8, 2020
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab Alone (17.7 months) Following Response to Platinum-Based Chemotherapy with…
May 8, 2020
NOXXON Announces Capital Increase of € 5.5 Million by Private Placement to Further Develop Its Business
BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) a biotechnology company focused on improving cancer treatments by targeting…
May 8, 2020
Identifying Critical Pharma Logistics Challenges in Canada | Infiniti’s Recent Article Offered Unprecedented Insights
LONDON–(BUSINESS WIRE)–#CompetitiveIntelligence–A well-known market intelligence company, Infiniti Research, has partnered with several global companies across industries to help meet their…
May 8, 2020
RedHill to further test opaganib with Covid-19 patients
RedHill Biopharma bagged approval from USFDA for its Investigational New Drug (IND) application for a Phase 2a clinical study to test its investigational drug, opaganib in patients with confirmed moderate-to-severe SARS-CoV-2 infection (the cause of COVID-19).
May 8, 2020
Role of Pharmacovigilance in Precision Medicine Market
Request FREE Proposal for Comprehensive Insights LONDON–(BUSINESS WIRE)–#Analytics–Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions…
May 8, 2020
AtriCure Announces Results from CONVERGE IDE Clinical Trial
Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid…
May 8, 2020
jCyte Inc. in $252 million deal for jCell Therapy with Santen Pharmaceutical
jCyte has entered a deal worth up to $252 million, including milestone payments of up to $190 million in potential milestones and royalties on net commercial sales for jCell.